GSK’s Dovato Matches Efficacy of Gilead’s Biktarvy in Head-to-Head HIV Trial

In the largest study of its kind, GSK’s two-drug regimen Dovato demonstrated non-inferior efficacy compared to Gilead Sciences’ three-drug regimen Biktarvy for the treatment of HIV-1.